MRD: A Key Predictor of Clinical Outcomes in Acute Lymphoblastic Leukemia
Published: Tuesday, Jul 09, 2019
Annie Im, MD
Assessing for minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) is imperative, as it can be used to predict clinical outcomes, such as relapse and survival in patients, said Annie Im, MD.
... to read the full story